|
Market Closed -
Nasdaq Stockholm
02:00:00 03/10/26 am AEST
|
5-day change | 1st Jan Change | ||
| 3.530 SEK | -1.12% |
|
+15.74% | +140.14% |
Company Valuation: Sprint Bioscience AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 191.1 | 22.03 | 121.1 | 110.5 | 155.1 | 372.5 | - |
| Change | - | -88.47% | 449.78% | -8.82% | 40.43% | 140.14% | - |
| Enterprise Value (EV) | 120.4 | -7.459 | 71.2 | 85.4 | 155.1 | 372.5 | 372.5 |
| Change | - | -106.19% | 1,054.57% | 19.94% | 81.63% | 140.14% | 0% |
| P/E | -5.64x | - | - | - | - | - | - |
| PBR | - | - | - | - | - | - | - |
| PEG | - | - | - | - | - | - | - |
| Capitalization / Revenue | 5.44x | 265x | 2.4x | 1.68x | 0.93x | 4.29x | 3.85x |
| EV / Revenue | 0x | -0x | 0x | 0x | 0x | 4.29x | 3.85x |
| EV / EBITDA | -0x | 0x | -0x | -0x | 0x | 13.9x | 9.67x |
| EV / EBIT | -0x | 0x | -0x | -0x | 0x | 14.5x | 9.93x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.85 | - | - | - | - | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 35.11 | 0.083 | 50.48 | 65.64 | 167.2 | 86.8 | 96.8 |
| EBITDA 1 | -25.04 | -60.12 | -0.398 | -18.71 | 98.36 | 26.8 | 38.5 |
| EBIT 1 | -25.63 | -60.74 | -0.845 | -19.67 | 97.29 | 25.7 | 37.5 |
| Net income | -25.08 | - | - | - | - | - | - |
| Net Debt | -70.64 | -29.49 | -49.93 | -25.06 | - | - | - |
| Reference price 2 | 4.795 | 0.553 | 1.735 | 1.582 | 1.470 | 3.530 | 3.530 |
| Nbr of stocks (in thousands) | 39,844 | 39,844 | 69,820 | 69,820 | 105,516 | 105,516 | - |
| Announcement Date | 16/2/22 | 15/2/23 | 14/2/24 | 12/2/25 | 11/2/26 | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 37.11M | |
| 21.73x | 7.71x | 15.48x | 1.37% | 74.16B | |
| 29.82x | 8.57x | 26.7x | 0.04% | 57.39B | |
| 32.98x | 5.93x | 17.77x | 0.98% | 47.64B | |
| -21.31x | 230.81x | -22.97x | -.--% | 44.29B | |
| 33.26x | 3.23x | 13.97x | -.--% | 42.5B | |
| 46.77x | 5.41x | 29.66x | -.--% | 40.71B | |
| 27.63x | 7.93x | 20.48x | 0.41% | 30.97B | |
| 32.99x | 7.05x | 18.3x | -.--% | 28.53B | |
| -15.1x | 5.68x | -7.14x | -.--% | 24.34B | |
| Average | 20.98x | 31.37x | 12.47x | 0.31% | 39.06B | |
| Weighted average by Cap. | 22.27x | 32.04x | 13.55x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SPRINT Stock
- Valuation Sprint Bioscience AB
Select your edition
All financial news and data tailored to specific country editions
